Teva Pharmaceutical Industries Ltd. Engages with Investors
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), a global leader in pharmaceuticals, is set to make a significant impression at the Jefferies London Healthcare Conference. Richard Francis, the President and CEO of Teva, will deliver a presentation that highlights the company's strategic initiatives and future directions.
Presentation Details
The conference is scheduled for a day in mid-November, where interested parties can tune in to hear Teva's insights and plans. Richard Francis's presentation will start at 8:30 A.M. GMT, providing investors and stakeholders with critical updates on the company's progress and strategic focus.
Accessing the Presentation
Those wishing to follow the presentation can access a live webcast on Teva's Investor Relations website. This platform will ensure that all vital information is readily available to those unable to attend in person. An archived version of the session will also be accessible within 24 hours after the live presentation. This caters to investors and analysts who want to revisit the highlighted topics or who may not be able to join the live session.
About Teva Pharmaceuticals
Teva has a long-standing commitment to innovation, leveraging its extensive experience in generics and investing in modern treatments. The company's global workforce, comprising approximately 37,000 employees, operates across 58 markets, continuously striving to enhance the health outcomes of millions of patients. With over a century of expertise, Teva aims to balance the delivery of quality medicines with advancement in scientific research.
Commitment to Health Improvement
Teva Pharmaceuticals' mission is founded on the principle of improving health standards globally. The company not only focuses on maintaining a robust generics portfolio but is also expanding its innovative medicines pipeline and exploring biosimilars. This growth trajectory reinforces Teva’s position as a dominant player in the pharmaceutical industry, actively contributing to healthcare advancement.
Investor Relations Contacts
For further inquiries, Teva maintains dedicated investor relations contacts. Reaching out to these professionals can provide additional insights and clarifications:
- Ran Meir: +1 (215) 591-8912
- Yael Ashman: +972 (3) 914 8262
- Sanjeev Sharma: +1 (973) 658 2700
Public Relations Contacts
Additionally, those interested in public relations can connect with:
- Kelley Dougherty: +1 (973) 832-2810
- Eden Klein: +972 (3) 906 2645
Frequently Asked Questions
What is the focus of Teva's upcoming presentation?
Teva's presentation will emphasize the company's strategic initiatives, advancements in their innovative drug pipeline, and future business directions at the Jefferies London Healthcare Conference.
How can I access the presentation?
You can watch the live webcast of the presentation through Teva's Investor Relations website, and an archived version will be available shortly after the event.
What is Teva Pharmaceuticals known for?
Teva is recognized as a leading global pharmaceutical company, specializing in generics, biosimilars, and innovative medicines, with a commitment to improving health outcomes worldwide.
Who can I contact for investor or PR inquiries?
Teva has dedicated professionals in their investor relations and public relations teams who can assist with inquiries, including specific contact details available for each representative.
What are Teva's core values?
Teva emphasizes innovation, quality, and accessibility in healthcare, striving to enhance the health landscape for individuals across various demographics and geographies.
